Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04704934
Title Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Daiichi Sankyo, Inc.

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma


Paclitaxel + Ramucirumab

Trastuzumab deruxtecan

Age Groups: adult | senior
Covered Countries ITA | FRA | ESP | DEU | BEL

No variant requirements are available.